AI-generated analysis. Always verify with the original filing.
Decoy Therapeutics Inc. filed a Certificate of Amendment on March 5, 2026, to effect a 1-for-12 reverse stock split of its common stock, effective 5:00 p.m. ET on March 6, 2026, reducing outstanding shares from approximately 6.38 million to 532,000 to comply with Nasdaq's continued listing requirements. Trading on a split-adjusted basis under ticker DCOY and new CUSIP 79400X602 begins March 9, 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
Material Modification to Rights of Security Holders. To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Rep
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. As previously disclosed, on February 24, 2026, at the 2026 Annual Meeting of Stockhold
Other Events. On August 14, 2025, the Company issued a press release announcing the reverse split. A copy of the press release is filed herewith as Exhibit 99.1
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 3.1 Certificate of Amendment (Reverse Stock Split) to the Amended and Restate